Johnson & Johnson (NYSE: JNJ)reported first-quarter 2018 results this week that outpaced industry watchers' forecasts. Its $20 billion in quarterly revenue clocked in over $600 million higher than expected and its adjusted earnings per share of $2.06 beat analysts by $0.05. There were a lot of contributors to the company's outperformance last quarter, but sales growth for Darzalex, Stelara, and Zytiga provided the biggest tailwinds.
3 Drugs That Are Moving the Needle at Johnson & Johnson
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться